Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1E | P49674 | 1/20 | 0.31 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.31 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.31 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.31 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.31 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.31 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.31 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.31 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.31 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.31 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.31 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.31 |
| ▸ | FLT3 | P36888 | 1/20 | 0.30 |
| ▸ | TLR7 | Q9NYK1 | 4/20 | 0.30 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.30 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7321101 | 0.91 | GRIN2D (0.34) | GRIN2DGRIN3BGRIA1GRIA2GRIA3 | |
| SCHEMBL14668767 | 0.79 | CSNK1E (0.30) | CSNK1E | |
| SCHEMBL11260324 | 0.79 | TLR7 (0.32) | TLR7 | |
| SCHEMBL2179909 | 0.79 | FLT3 (0.32) | CSNK1EFLT3 | |
| SCHEMBL8240168 | 0.79 | CSNK1E (0.33) | CSNK1EFLT3TLR7 | |
| SCHEMBL25080099 | 0.79 | GRIN2D (0.33) | CSNK1EGRIN2DGRIN3BGRIA1GRIA2 | |
| SCHEMBL18248807 | 0.75 | GRIN2D (0.33) | GRIN2DGRIN3BGRIA1GRIA2GRIA3 | |
| SCHEMBL20294418 | 0.75 | HCRTR1 (0.32) | HCRTR1HCRTR2 | |
| SCHEMBL18248843 | 0.75 | HCRTR2 (0.32) | HCRTR1HCRTR2 | |
| SCHEMBL14164486 | 0.74 | CYP17A1 (0.42) | FLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180370973-A1 | FUSED HETEROARYL DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2018-12-27 | — | — | US | disclosed |
| WO-2016106106-A2 | FUSED HETEROARYL DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-06-30 | — | — | WO | disclosed |
| WO-2016101119-A1 | FUSED HETEROARYL DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-06-30 | — | — | WO | disclosed |
| WO-2016106106-A2 | FUSED HETEROARYL DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-06-30 | — | — | WO | disclosed |
| EP-0013914-B1 | PIPERAZINYL-IMIDAZO(1,2-A)PYRAZINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | MERCK & CO. INC. (US) | 1982-12-15 | — | — | EP | disclosed |
| US-4242344-A | ANOREXIGENIC, HYPOTENSIVE, ANTISMOKING, AND ANTIARRYTHMIA AGENTS; ANTIDEPRESSANTS; ANALGESICS | MERCK & CO., INC. (US) | 1980-12-30 | — | — | US | disclosed |
| EP-0013914-A1 | Piperazinyl-imidazo(1,2-a)pyrazine derivatives, process for their preparation and pharmaceutical compositions containing them | MERCK & CO. INC. (US) | 1980-08-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180370973-A1 | FUSED HETEROARYL DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, OXTR | CSNK1E 3386/4885GRIN2D 200/4885GRIN3B 101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.